Efficacy and safety of rh‐endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh‐endostatin plus pemetrexed maintenance in non‐small cell lung cancer: A retrospective comparison with standard chemotherapy

Zhou, Shengyu; Zuo, Li; He, Xiaohong; Pi, Jinping; Jin, Jun; Shi, Yuankai

doi:10.1111/1759-7714.12827

Cited by 15 publications

(12 citation statements)

References 22 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the incidence of complete response in gastroesophageal cancer patients treated with targeted agents has been reported to be 2.0%, only 0.3 increase from the control arms [17]. ErbB receptor-targeting inhibitors failed to show any significant differences on overall response rate, clinical benefit rate and overall survival, with the increased risk of serious adverse events [18]. Likewise, cyclin-dependent kinase inhibitor combined with chemotherapy slightly increased the mean progression-free survival but also stimulated the senescence-associated (SA) marker expression (assessed by the accumulation of by SA β-galactosidase in the lysosome) by yet unknown mechanism [19].…”

Section: Chromone Derivatives As New Type Of Anticancer Candidatementioning

confidence: 99%

Recent Progress of Basic Studies of Natural Products and Their Dental Application

et al. 2018

View full text Add to dashboard Cite

The present article reviews the research progress of three major polyphenols (tannins, flavonoids and lignin carbohydrate complexes), chromone (backbone structure of flavonoids) and herbal extracts. Chemical modified chromone derivatives showed highly specific toxicity against human oral squamous cell carcinoma cell lines, with much lower toxicity against human oral keratinocytes, as compared with various anticancer drugs. QSAR analysis suggests the possible correlation between their tumor-specificity and three-dimensional molecular shape. Condensed tannins in the tea extracts inactivated the glucosyltransferase enzymes, involved in the biofilm formation. Lignin-carbohydrate complexes (prepared by alkaline extraction and acid-precipitation) and crude alkaline extract of the leaves of Sasa species (SE, available as an over-the-counter drug) showed much higher anti-HIV activity, than tannins, flavonoids and Japanese traditional medicine (Kampo). Long-term treatment with SE and several Kampo medicines showed an anti-inflammatory and anti-oxidant effects in small size of clinical trials. Although the anti-periodontitis activity of synthetic angiotensin II blockers has been suggested in many papers, natural angiotensin II blockers has not yet been tested for their possible anti-periodontitis activity. There should be still many unknown substances that are useful for treating the oral diseases in the natural kingdom.

show abstract

Section: Chromone Derivatives As New Type Of Anticancer Candidatementioning

confidence: 99%

Recent Progress of Basic Studies of Natural Products and Their Dental Application

et al. 2018

View full text Add to dashboard Cite

show abstract

“…It has been reported that Endostar combined with platinum-doublet chemotherapy, including vinorelbine, gemcitabine, paclitaxel, can prolong the survival time for those patients with good performance status in advanced LSCC, and has been recommended as the first-line choice, boasting 6.0-7.2 and 13.6-19.0 months of median PFS and OS, respectively (5,6). However, the trend of improved survival time in advanced NSCLC patients administered maintenance treatment is still disputed (7,8). Owing to its potential and promising benefits, emerging studies, including the latest HELPER study (9), have added insight into the effects of Endostar in combination with CRT in advanced NSCLC patients (10,11).…”

Section: Introductionmentioning

confidence: 99%

Endostar improved efficacy of concurrent chemoradiotherapy with vinorelbine plus carboplatin in locally advanced lung squamous cell carcinoma patients with high serum Lp(a) concentration

Meng

et al. 2020

Ann Palliat Med

View full text Add to dashboard Cite

Background: The role of vascular targeting therapy combined with concurrent chemoradiotherapy (CRT) has produced many inconsistent results in locally advanced non-small-cell lung cancer (NSCLC), especially in lung squamous cell carcinoma (LSCC). Lipoprotein (a) [Lp(a)] may be critical in the development of tumor angiogenesis, and its levels are individualized and determined genetically. This study aimed to determine whether Lp(a) is correlated with effects of recombinant human endostatin (Endostar) combined with concurrent CRT for locally advanced LSCC. Methods: Patients with locally advanced LSCC from December 2008 to December 2017 were retrospectively analyzed. Patients were divided into two groups: (I) a chemoradiotherapy group (CRT group) which received weekly vinorelbine and carboplatin concurrently with radiotherapy 60Gy, and (II) an Endostar in combination with chemoradiotherapy group (ECRT group) which received Endostar intravenous drip for 1-14 days (every 3 weeks) concurrently with CRT. Fasting venous blood samples for serum Lp(a) in all patients were collected before the treatment. The effect of Endostar was assessed by stratified analysis. Results: A total of 94 patients were recruited in this study. There were 59 cases in the CRT group and 35 cases in the ECRT group. Overall, the median progression-free survival (PFS) was 9.6 vs. 14.2 months (P=0.0671), and the overall survival (OS) was 15.0 vs. 20.6 months (P=0.114), in the CRT and ECRT groups respectively. The median of Lp(a) was 218 mg/L. In patients with serum Lp(a) less than 218 mg/L, the median PFS was 10.0 vs. 9.4 months (P=0.406), and the OS was 15.4 vs. 16.3 months (P=0.958) in the CRT and ECRT groups, respectively. However, in patients with serum Lp(a) higher than 218mg/L, the median PFS was 9.0 vs.15.8 months (P=0.011), and the OS was 14.0 vs. 21.1 months (P=0.055), in the CRT and ECRT groups, respectively. Cox proportional hazard model analysis revealed that a high concentration of Lp(a), ≥218 mg/L, is a prognostic factor for PFS [hazard rate (HR), 0.43 (0.23-0.81)] and OS [HR, 0.52 (0.27-0.98)] in locally advanced LSCC (P<0.05). Conclusions: The serum concentration of Lp(a) may serve as a biomarker to identify the patients who would benefit from Endostar treatment with concurrent CRT in stage III LSCC. Xu et al. Endostar improved efficacy of high Lp(a) LSCC

show abstract

“…These abnormal blood vessels impair the supply of oxygen and results in radiation resistance [ 26 , 27 ]. Endostar is a recombinant human endostatin that targets new capillary endothelial cells around tumors [ 28 ]. Endostar shows an antitumor effect when it is used together with chemotherapy [ 28 – 30 ].…”

Section: Discussionmentioning

confidence: 99%

“…Endostar is a recombinant human endostatin that targets new capillary endothelial cells around tumors [ 28 ]. Endostar shows an antitumor effect when it is used together with chemotherapy [ 28 – 30 ]. An in vitro study showed that Endostar inhibits the VEGF signal pathways and thus increases the efficacy of radiotherapy [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

Chemoradiotherapy and Increased Prescription Dose in Esophageal Squamous Cell Cancer: A Retrospective Study

Pan

Liao

Ma³

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

To analyze the outcomes and adverse events of patients with esophageal squamous cell carcinoma (ESCC) treated with definitive chemoradiation with modified radiotherapy volume and increased radiation dose. This was a retrospective analysis of patients with ESCC treated with definitive chemoradiotherapy at the Sun Yat-sen University Cancer Center (02/2015 to 02/2017). The dose to the planning gross tumor volume (PGTV) and planning clinical tumor volume (PTV1) was 66-68 Gy (2.0-2.2 Gy/fraction). The dose to the planning regional lymph node drainage area volume (PTV2) was 46 Gy (2.0 Gy/fraction). Treatment response, adverse events, progression-free survival (PFS), overall survival (OS), and locoregional failure-free survival (LRFFS) were analyzed. Twenty-six patients were included. The median follow-up was 31 (range, 4.3-51.3) months. Sixteen (61.5%) patients had a complete response, and four (15.4%) achieved a partial response. The objective response rate was 76.9%, and the disease control rate was 80.8%. The median PFS and OS were not achieved. The 4-year PFS was 63.9%, and the 4-year OS was 71.0%. Grade 1-2 and 3-4 radiation-related esophagitis was observed in 15 (57.7%) and one (4.5%) patients, respectively. Grade 1-2 and 3-4 radiation-related pneumonitis was observed in 12 (46.2%) and one (4.5%) patients, respectively. No patients developed radiation-related heart or skin damage. The modified target volume definition and increased dose of definitive radiotherapy combined with chemotherapy in patients with ESCC had low toxicity and might improve survival, but additional trials are necessary to prove the superiority of this strategy.

show abstract

Efficacy and safety of rh‐endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh‐endostatin plus pemetrexed maintenance in non‐small cell lung cancer: A retrospective comparison with standard chemotherapy

Cited by 15 publications

References 22 publications

Recent Progress of Basic Studies of Natural Products and Their Dental Application

Recent Progress of Basic Studies of Natural Products and Their Dental Application

Endostar improved efficacy of concurrent chemoradiotherapy with vinorelbine plus carboplatin in locally advanced lung squamous cell carcinoma patients with high serum Lp(a) concentration

Chemoradiotherapy and Increased Prescription Dose in Esophageal Squamous Cell Cancer: A Retrospective Study

Contact Info

Product

Resources

About